Product Description
Didanosin Delayed Release Capsules are a best-seller in antiretroviral therapy, offering top-ranking effectiveness for the management of HIV-1 infection in adults and children. Available in 250 mg and 400 mg strengths, these value-packed capsules feature white to off-white granules in a protective bottle, helping deliver the perfect dose every time. Manufactured in a WHO-GMP and ISO-certified facility in India, Didanosin provides reduced side effects with its delayed-release formula. Prescription-only, it is not suitable for monotherapy and should be used as directed by a physician.
Crowning Solution for Combination HIV Therapy
Didanosin Delayed Release Capsules are designed specifically for HIV-infected adults and pediatric patients, ideal for use in combination with other antiretroviral medications. These capsules are perfect for those requiring a robust oral treatment that delivers precise dosing and enhanced patient compliance. Patients benefit from a reduced risk of resistance due to this combination approach, with each bottle containing 30 capsules suitable for both adults and children. Adherence to prescribed regimens ensures maximum therapy advantage.
Sample Outlay and Supply Rate Specifications
Samples of Didanosin Delayed Release Capsules are available upon proposal amount agreement, enabling professionals to evaluate suitability before committing to bulk procurement. With a steady rate of supply and reliably secure packaging-each bottle containing 30 capsules and protected from moisture-the product ensures quality and longevity in storage. Detailed packaging meets export, supplier, and trader requirements out of India, making stock management seamless and outlay-effective for distributors and healthcare providers.
FAQ's of Didanosin Delayed Release Capsules:
Q: How should Didanosin Delayed Release Capsules be administered for best effectiveness?
A: Didanosin Delayed Release Capsules must be taken orally on an empty stomach, either 30 minutes before or two hours after eating, to ensure proper absorption and optimal efficacy.
Q: What are the key warnings associated with using Didanosin Delayed Release Capsules?
A: These capsules should never be used as monotherapy and require regular monitoring for signs of pancreatitis or lactic acidosis. Do not use in individuals with hypersensitivity to didanosine or a history of pancreatitis.
Q: When should Didanosin Delayed Release Capsules be considered in HIV treatment?
A: Didanosin is indicated for use in combination with other antiretroviral agents for the management of HIV-1 infection in adults and pediatric patients, as directed by a healthcare provider.
Q: Where are Didanosin Delayed Release Capsules manufactured and how can I verify quality?
A: Manufactured in India in a WHO-GMP and ISO-certified facility, the product's packaging includes market distributor information to help verify authenticity and supplier details.
Q: What is the benefit of the delayed-release formulation in Didanosin Capsules?
A: The delayed-release formulation helps reduce gastrointestinal side effects and supports more consistent absorption, contributing to better patient tolerance and adherence to therapy.